RETA लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Sep 2023 @ 01:30):

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...

Stats
आज की मात्रा	1.91M
औसत मात्रा	954 093
बाजार मूल्य	6.57B
EPS	$0 ( 2024-02-22 )
अगली कमाई की तारीख	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-66.29
ATR14	$1.830 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-26	Desai Antal Rohit	Sell	134	Class A common stock
2023-09-26	Desai Antal Rohit	Sell	993 929	Class B common stock
2023-09-26	Mcgaughy R Kent Jr	Sell	280	Class A common stock
2023-09-26	Mcgaughy R Kent Jr	Sell	278 309	Class B common stock
2023-09-26	Mcgaughy R Kent Jr	Sell	699	Stock Option (right to buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 4 695 639

मात्रा सहसंबंध

लंबा: 0.09 (neutral)

छोटा: -0.26 (neutral)

Signal:(84.692) Neutral

Reata Pharmaceuticals Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
CREX	0.957
MYRG	0.875
ALLR	0.869
MSSA	0.849
SGEN	0.847
NETE	0.835
PLYA	0.832
MHUA	0.831
USAP	0.83
SGTX	0.825

10 सबसे अधिक नकारात्मक सहसंबंध
RMGBU	-0.875
ENVI	-0.851
EJFA	-0.838
ONEM	-0.837
ESSA	-0.837
SVOK	-0.824
SAII	-0.819
FNCB	-0.818
BSBK	-0.816
PAIC	-0.814

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Reata Pharmaceuticals Inc सहसंबंध - मुद्रा/वस्त्र

-0.73
( moderate negative )

-0.79
( moderate negative )

0.49
( neutral )

-0.76
( moderate negative )

0.19
( neutral )

0.78
( moderate )

Reata Pharmaceuticals Inc वित्तीय

Annual	2022
राजस्व:	$2.22M
सकल लाभ:	$2.22M (100.00 %)
EPS:	$-8.59

FY	2022
राजस्व:	$2.22M
सकल लाभ:	$2.22M (100.00 %)
EPS:	$-8.59

FY	2021
राजस्व:	$11.49M
सकल लाभ:	$11.49M (100.00 %)
EPS:	$-8.19

FY	2020
राजस्व:	$9.02M
सकल लाभ:	$9.02M (100.00 %)
EPS:	$-7.35

Financial Reports:

No articles found.

Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.